NABOTA 200U

Nabota 200U is the large vial of botulinum toxin type A preparation from Daewoong Pharmaceutical in the Republic of Korea. It contains 200 units as a lyophilisate, which is reconstituted with sterile saline solution before use. For those who regularly treat areas with a high unit requirement, this vial size is more economical than using several smaller ones – and at the same time, they retain control over the concentration because they can set it themselves.

What the 200-unit bottle is intended for

200 units is not a sufficient quantity for occasional Glabella appointments. It is only cost-effective where many units are needed per session or where several patients are treated consecutively on the same day. In practice, this typically means:

• Practices with fixed toxin consultation hours instead of scattered individual appointments.
• Treatment areas with a high unit requirement, where a 100-unit bottle quickly reaches its limit.
• Facilities that combine multiple regions in one session
• Users who consistently use a specific dilution and therefore need a larger starting volume.

The downside is the same as with any toxin: what remains after the treatment is waste. A large bottle is only worthwhile if you use it frequently. Those who treat irregularly are better off with smaller containers.

Reconstitution: They determine the concentration

Nabota is supplied as a powder and must be dissolved in sterile, preservative-free saline solution (0.9%) before use. This is one more step than with a ready-to-use solution – but it also offers more flexibility: the amount of Nabota dissolved determines how many units are contained in 0.1 ml.

Dilution scheme for 200 units

The table is purely for calculation purposes, not a recommendation. The appropriate dilution depends on the area being treated and the application technique: lower volumes for targeted application, higher volumes where a wider distribution is desired. The official manufacturer's instructions and the applicable technical information are authoritative.

Practical advice: The concentration must be consistently defined and documented within a practice. If dilution is performed to 2.5 ml today and to 4 ml tomorrow, the same syringe marking on two different days will result in two different doses. This is a classic source of error with lyophilized tablets – and the reason why some practices deliberately opt for ready-to-use preparations.

After dissolving

The reconstituted solution should be kept refrigerated and used within the time frame specified by the manufacturer. Any unused portion should be disposed of properly. When dissolving the solution, the saline solution should be added along the side of the ampoule, and the bottle should be gently swirled rather than shaken – botulinum toxin is a protein and is sensitive to shear forces.

Nabota 200U – Product Data

Areas of application and dosage

The specific indications covered depend on the applicable approval in the respective country. Botulinum toxin type A is used in the medical field for both selected therapeutic and aesthetic applications.

The dose is determined by the indication, muscle activity, individual anatomy, and treatment goal. Dosage regimens differ significantly depending on the area being treated, and the selection of suitable patients, the injection technique, and the determination of the dose are the responsibility of the treating physician.

One point that is regularly underestimated when switching preparations: Units from different botulinum toxin manufacturers are based on their own testing procedures and are not a common currency. Those switching from another toxin to Nabota cannot simply transfer their usual number of units, but need to determine their own dosage.

Onset and duration of action

Initial effects can be seen within a few days of treatment. The full clinical result is often available after about two weeks – this is also the usual time for follow-up appointments. The duration of the effect varies from person to person and depends on the dose, muscle activity, treated area, and patient-specific factors.

Preparation and handling

The official manufacturer's instructions must be followed before each use. All steps – reconstitution, drawing up, injection – are performed under aseptic conditions. After reconstitution, the solution is checked: clear, colorless, and free of visible particles. Any abnormalities preclude its use.

Batch number and expiration date are recorded before use. Any unused product residue must be disposed of properly.

Safety, contraindications and side effects

A complete medical history is taken before every treatment. Contraindications, known hypersensitivities, and other medical reasons against treatment must be ruled out – these include, in particular, neuromuscular diseases such as myasthenia gravis, infections at the planned injection site, as well as pregnancy and breastfeeding. Explanation of the benefits and risks is an integral part of every therapy.

Pain, redness, swelling, or bruising at the injection site, as well as headaches, are frequently reported. Depending on the treated area, temporary functional changes may occur, such as ptosis or asymmetrical facial expression. All adverse events should be documented and evaluated according to current medical standards.

Patients should be informed about the rare signs of toxin spread: difficulty swallowing, speaking, or seeing; pronounced general muscle weakness; and breathing difficulties. In these cases, immediate medical attention is required.

Documentation and traceability

Batch documentation for biological drugs is not merely a formality. It should record the indication, dose, batch number, treated area, and the result of any follow-up examination. If a query arises later – due to lack of effect, an unexpected reaction, or the manufacturer's batch information – this is the only basis on which anything can be reconstructed.

Standardized treatment protocols and regular training also help to ensure that results remain comparable within a practice, even when several practitioners are involved.

Nabota compared to ready-to-use toxins

The difference lies not in the active ingredient, but in the formulation – and thus in the workflow.

For those who wish to vary the concentration depending on the area being treated, a lyophilisate is a better option. For those who want to save preparation time and avoid dilution errors, Innotox 100U is the ready-to-use alternative – and Innotox 50U for smaller quantities . Both are Korean botulinum toxin type A preparations; they differ in manufacturer, formulation, and unit system.

Approval status in Germany

Precise wording is important here because it differs for Nabota compared to most Korean toxins:

The active ingredient is approved in the EU – as Nuceiva , since September 27, 2019, with Evolus Pharma BV as the marketing authorization holder. Nuceiva has been available in Germany since February 2023. However, Nabota 200U, a Korean marketed product, is distinct : different trade name, different marketing authorization holder, different presentation. There is no German marketing authorization for the Korean Nabota marketed product.

The procurement and use of this product are subject to the provisions of the German Medicines Act (AMG), in particular Section 73 concerning the importation of unauthorized medicinal products. The responsibility for verification lies with you as the prescribing physician. We provide the product information; however, only expert legal advice can provide a definitive assessment of your specific case.

Frequently asked questions about Nabota 200U

Is Nabota the same as Jeuveau or Nuceiva?

It is the same active ingredient from Daewoong, marketed under different brand names depending on the market: Nabota in Korea, Jeuveau in the USA, Nuceiva in the EU. However, the marketing authorization holder and presentation differ – Nabota 200U is not the EU-approved Nuceiva.

Does Nabota 200U need to be reconstituted?

Yes. Nabota is a lyophilisate and is dissolved in sterile, preservative-free 0.9% saline solution before use.

How many units are there after dissolving in 0.1 ml?

This depends on the volume added. For 2.5 ml, it's 8 units per 0.1 ml; for 4 ml, 5 units; and for 5 ml, 4 units. The complete overview is shown in the dilution chart above.

Is Nabota "Korean Botox"?

The term is used colloquially, but it is technically inaccurate. Botox® is a registered trademark of Allergan for a different product. Nabota is a product of Daewoong. Both contain botulinum toxin type A, but are different medications with non-transferable units.

When is the 200-bottle more economical than smaller containers?

For predictable capacity utilization and areas with high unit demand. Since residual quantities are discarded, the actual usage per bottle is the deciding factor – not the price per unit in the offer.

Does Nabota contain human serum albumin?

Nabota is a lyophilisate containing albumin. If you are looking for a preparation without human serum albumin and without animal-derived ingredients, Innotox is the appropriate alternative. Please refer to the manufacturer's documentation for the delivered batch for the exact composition.

How is Nabota stored?

Store according to the manufacturer's instructions, generally at 2–8 °C and protected from light. Do not freeze. After reconstitution, the manufacturer's instructions regarding the shelf life apply.